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Massive intravascular hemolysis is associated with acute kidney injury (AKI). Nuclear factor 
erythroid-2-related factor 2 (Nrf2) plays a central role in the defense against oxidative 
stress by activating the expression of antioxidant proteins. We investigated the role of 
Nrf2 in intravascular hemolysis and whether Nrf2 activation protected against hemoglobin 
(Hb)/heme-mediated renal damage in vivo and in vitro. We observed renal Nrf2 activation 
in human hemolysis and in an experimental model of intravascular hemolysis promoted 
by phenylhydrazine intraperitoneal injection. In wild-type mice, Hb/heme released from 
intravascular hemolysis promoted AKI, resulting in decreased renal function, enhanced 
expression of tubular injury markers (KIM-1 and NGAL), oxidative and endoplasmic 
reticulum stress (ER), and cell death. These features were more severe in Nrf2-deficient 
mice, which showed decreased expression of Nrf2-related antioxidant enzymes, including 
heme oxygenase 1 (HO-1) and ferritin. Nrf2 activation with sulforaphane protected against 
Hb toxicity in mice and cultured tubular epithelial cells, ameliorating renal function and 
kidney injury and reducing cell stress and death. Nrf2 genotype or sulforaphane treatment 
did not influence the severity of hemolysis. In conclusion, our study identifies Nrf2 as a 
key molecule involved in protection against renal damage associated with hemolysis and 
opens novel therapeutic approaches to prevent renal damage in patients with severe 
hemolytic crisis. These findings provide new insights into novel aspects of Hb-mediated 
renal toxicity and may have important therapeutic implications for intravascular hemolysis-
related diseases.
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INTRODUCTION
Recurrent and massive intravascular hemolysis induces renal 
toxicity, leading to acute kidney injury (AKI) and increasing the 
risk to develop chronic kidney disease (CKD) (Moreno et al., 
2012; Naik et al., 2014). Intravascular hemolysis is a common 
characteristic of diseases such as sickle cell disease (SCD), 
paroxysmal nocturnal hemoglobinuria, hemolytic uremic 
syndrome, thrombotic thrombocytopenic purpura, and surgical 
procedures, including cardiopulmonary bypass or percutaneous 
mechanical thrombectomy (Ballarin et al., 2011; Baddam et al., 
2017; Escobar et al., 2017; Mammen et al., 2017; Wetz et al., 2017; 
Guerrero-Hue et al., 2018).
Erythrocyte destruction leads to the release of hemoglobin 
(Hb) and heme-derived products to plasma, which are then 
filtered by kidney glomeruli and reabsorbed by the proximal 
tubular epithelium. Renal cell exposure to Hb and metabolites 
promotes side effects, such as inflammation, cell death, and 
oxidative stress characterized by lipid peroxidation and 
mitochondrial dysfunction (Balla et al., 1993; McFaul et al., 
1994; Reiter et al., 2002; Liu and Spolarics 2003; Gonzalez-
Michaca et al., 2004). Thus, in an oxidant milieu, heme-
derived iron group may be oxidized, producing hydroxyl and 
hydroperoxyl radicals (Gutteridge, 1986). These radicals are 
highly reactive and promote the formation of reactive oxygen 
species and subsequent lipid peroxidation and DNA damage (Jia 
et al., 2007; Buehler et al., 2010). Endoplasmic reticulum (ER) 
stress, a common form of cell stress, has recently emerged as 
a pathophysiologic mechanism underlying the renal damage 
associated with Hb and heme accumulation (Deuel et al., 2016; 
Feng et al., 2018). ER stress is generated by the accumulation 
of misfolded proteins in the ER, initiating the unfolded protein 
response (UPR) that also can be triggered by several insults 
such as inhibition of proteasome, hypoxia, and oxidative stress 
(Kim et al., 2008; Liu et al., 2019). UPR compensates stress 
maintaining cellular homeostasis and avoiding cell death. Heme 
induces ER stress by expression of activating transcription 
factor-4 (ATF4) as well as splicing of X-box binding protein-1 
(XBP1), promoting upregulation of targets such as CHOP (C/
EBP homology protein) (Gall et al., 2018). Administration of 
transferrin, hemopexin, and haptoglobin resulted in beneficial 
extravascular/intravascular hemolytic anemias (Buehler and 
Karnaukhova, 2018). However, it is necessary to unravel the 
pathogenesis of Hb-mediated renal damage to identify novel 
therapeutic targets to protect against AKI and subsequent 
progression to CKD.
Nuclear factor erythroid-2-related factor 2 (Nrf2) is a 
transcription factor that drives the expression of target genes 
involved in cellular defense against xenobiotics and cellular 
stress such as oxidative and ER stress (Itoh et al., 1997; 
Cullinan and Diehl, 2004; Chang et al., 2018). In these harmful 
conditions, Nrf2 is translocated into the nucleus and interacts 
with antioxidant response elements (AREs) to upregulate a 
battery of phase II and antioxidant enzymes, such as HO-1 (the 
enzyme that catalyzes heme degradation) and ferritin (involved 
in iron storage and with ferroxidase activity) (Tsuji et al., 
2000; Kobayashi and Yamamoto, 2006; Liu et al., 2009). Both 
proteins have been shown to be protective in heme-associated 
pathologies (Balla et al., 1992; Nath et al., 1992; Zarjou et al., 
2013). Several studies have shown that Nrf2 induction protects 
against oxidative stress and inflammation in AKI (Shelton 
et al., 2013; Zarjou et al., 2013). Interestingly, pharmacological 
activation of Nrf2/HO-1 pathway was found to significantly 
protect against rhabdomyolysis-induced AKI (Shelton et al., 
2013; Wang et al., 2014). Although Nrf2 activation has been 
postulated as a possible therapeutic target to treat diseases 
associated with intravascular hemolysis (Keleku-Lukwete et al., 
2015; Doss et al., 2016; Ghosh et al., 2016; Vasconcellos et al., 
2016; Belcher et al., 2017), additional studies are needed to 
unravel the specific effect of Nrf2 activation in kidney in this 
pathological setting. In the present study, we investigate the 
role of Nrf2 in Hb-induced AKI during intravascular hemolysis 
episodes in humans and in an experimental animal model 
resembling massive intravascular hemolysis. Nrf2 knockout 
mice showed more severe AKI. To further clarify the role of 
Nrf2 in AKI induced by intravascular hemolysis, we analyzed 
the expression of several Nrf2-related proteins. Finally, we also 
demonstrate that Nrf2 activation ameliorates AKI induced by 
intravascular hemolysis both in vivo and in cultured tubular 
epithelial cells, indicating that Nrf2 may be a therapeutic target 
for the treatment of these diseases.
MATERIAL AND METHODS
Human Renal Biopsy
We identified a renal biopsy from a 28-year-old patient with 
massive intravascular hemolysis secondary to percutaneous 
mechanical thrombectomy. At time of biopsy, the patient 
showed characteristics of AKI (sCr 9.78 mg/dl) and intravascular 
hemolysis (Hb 11 g/dl, platelets 180,000/µl, LDH 1,030 IU/L, and 
haptoglobin 5 mg/dl). Healthy kidney samples were obtained 
from non-tumor renal sections obtained after surgery in patients 
with kidney cancer and stored at the Instituto de Investigaciones 
Sanitarias-Fundacion Jimenez Diaz (IIS-FJD) biobank. Patients 
provided informed consent, and the biobank was approved by 
the IIS-FJD ethics committee.
Animal Model
Intravascular hemolysis was induced by the intraperitoneal 
administration of a freshly prepared phenylhydrazine solution 
(2 mg/10 g of body weight) in 12-week-old wild-type C57BL/6 
mice (Jackson Laboratory) or Nrf2-deficient mice (Nrf2−/−) 
(obtained from Dr. Susana Cadenas, CBMSO, Spain). Mice were 
housed in a pathogen-free, temperature-controlled environment 
with a 12-h/12-h light/dark photocycle and had free access 
to food and water. Phenylhydrazine hydrochloride (Sigma-
Aldrich) was dissolved in phosphate-buffered saline (PBS) at 
a concentration of 10  mg/ml, and the pH was adjusted to pH 
7.4 with NaOH. For Nrf2 activation, sulforaphane (12.5  mg/
kg of body weight, Cayman Chemical) was administrated 
intraperitoneally 48, 24, and 2 h before phenylhydrazine 
injection. At 24 h after phenylhydrazine injection, mice were 
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anesthetized (100 mg/kg of ketamine and 15 mg/kg of xylazine), 
saline perfused, and euthanized. Blood samples were collected 
for biochemistry analysis (ADVIA® 2400 Clinical Chemistry 
System, Siemens Healthcare) and hematological analysis (Scil 
Vet ABC hematology analyser; Scil). Urine samples were 
collected for measuring urinary creatinine (creatinine assay kit, 
Abcam). The presence of heme in tissue, blood, and urine was 
quantified with a commercial kit (MAK316, Sigma). Dissected 
kidneys were fixed in 4% paraformaldehyde and embedded in 
paraffin for histological studies or snap frozen for RNA and 
protein studies, as previously described (Moreno et al., 2011; 
Sastre et al., 2013). All reported experiments were conducted 
in accordance with the Directive 2010/63/EU of the European 
Parliament and were approved by a local Institutional Animal 
Care and Use Committee (IIS-FJD).
Immunohistochemistry/
Immunofluorescence
Paraffin-embedded kidneys were cross-sectioned into 3-μm-thick 
pieces, and immunohistochemistry/immunofluorescence was 
performed as previously described (Rubio-Navarro et al., 2016). 
Specific primary antibodies were rabbit anti-Hb (1:100 dilution, 
ab92492, Abcam), rabbit anti-HO-1 (1:200 dilution, ADI-
OSA-150-DEnzo Life technologies), rabbit anti-ferritin light 
chain (1:500 dilution, ab69090, Abcam), rabbit anti-phospho 
Nrf2 (1:50 dilution, bs-2013R, Bioss), Nrf2 (1:100 sc-722, 
Santa Cruz), rabbit anti-mouse 4-hydroxynonenal (4-HNE) 
(1:100, ab46545, Abcam), mouse anti-calnexin (1:100, 610523 
BD Biosciences), and mouse anti-BiP (1:100, sc376768, Santa 
Cruz). The biotinylated secondary antibodies were applied 
for 1 h. Avidin–biotin peroxidase complex (Vectastain ABC 
kit, PK-7200, Vector Laboratories) was added for 30 min. 
Sections were stained with 3,3′-diaminobenzidine or 3-amino-
9-ethyl carbazol (S1967, DAKO) and counterstained with 
hematoxylin. Images were taken with a Nikon Eclipse E400 
microscope (Japan) and Nikon ACT-1 software (Japan). In 
immunofluorescence studies, slides were incubated with Alexa 
488 as secondary antibodies (A11090, Invitrogen) and analyzed 
in an inverted confocal microscope (Leica TCS SP5). Nuclei 
were counterstained with 4′-6-diamidino-2-phenylindole 
(DAPI). Negative controls using the corresponding IgG were 
included to check for non-specific staining. Quantification of 
protein expression was performed using the Image-J software 
(National Institutes of Health, Bethesda, MD, USA) with similar 
acquisition settings in all tissues. Samples were examined in a 
blinded manner.
TUNEL Assay
The degree of apoptosis was assessed using a terminal 
deoxynucleotidyl transferase (TdT) dUTP nick-end labeling 
(TUNEL) assay. Detection of DNA fragmentation was performed 
using a kit from Roche Applied Sciences (06432344001, 
Indianapolis, IN, USA). A semi-quantitative analysis was 
performed by counting the number of TUNEL-positive cells per 
field in the renal tissue at ×400 magnification. At least 10 areas in 
the cortex per slide were randomly selected. The mean number 
of green colored cells in these selected fields was expressed as the 
number of TUNEL-positive cells.
Cell Culture
Proximal murine tubular epithelial (MCT) cells were cultured in 
RPMI 1640 (R0883, Sigma, MO, USA) supplemented with 10% 
decomplemented fetal bovine serum (FBS, F7524, Sigma, MO, 
USA), glutamine (2 mmol/L, G7513, Sigma, MO, USA), and 
penicillin/streptomycin (100 U/ml; P0781, Sigma, MO, USA) 
in 5% CO2 at 37°C. MCT cells were stimulated with Hb (0–500 
µg/ml, corresponding to 0–30 µM of heme molar equivalents) 
(H0267, Sigma) and hemin/heme (0–30 µM) (H9039, Sigma). 
Some cells were pre-treated with sulforaphane (SFN, 2 μM, 
Cayman Chemical) or tert-butyl hydroquinone (tBHQ, 1 µM) 
(112941, Sigma) for 16 h before Hb/heme stimulation.
Luciferase Assay in AREc32 Cell Cultures
Transformed MCF-7 breast cancer cells, stably expressing 
luciferase under the control of ARE sequences, AREc32 [kindly 
provided by Prof. Roland Wolf (University of Dundee, U.K.)], 
were cultured in DMEM with GlutaMAX and high glucose, 
supplemented with 1% penicillin-streptomycin (10,000 units), 
Geneticin (0.8 mg/ml), and 10% FBS at 37°C in a 5% CO2-
supplemented air atmosphere. Nrf2 was induced in AREc32 cells 
as previously described (Buendia et al., 2015). In brief, AREc32 
cells were seeded in 96-well white plates (2 × 104 cells/well). 
Twenty-four hours later, cells were treated with Hb (0–500 µg/ml, 
0–30 µM of heme molar equivalents) or heme (10 µM) for 
another 24 h. Thereafter, luciferase content was determined using 
a Luciferase Assay System (Promega E1500) and quantified in an 
Orion II microplate luminometer (Berthold, Germany).
RNA Extraction and Real-Time PCR
Total RNA from kidneys or cultured cells was isolated with TriPure 
reagent (Roche) and reverse transcribed with High Capacity 
cDNA Archive Kit (Applied Biosystems). Real-time PCR was 
performed on ABI Prism 7500 PCR system (Applied Biosystems, 
Foster City, CA, USA) using the DeltaDelta Ct method.
Expression of target genes was analyzed by real-time 
quantitative PCR using Taqman® gene expression assays for 
murine NGAL (Mm01324470_m1), KIM-1 (Mm00506686_m1), 
HO-1 (Mm00516005_m1), ferritin light chain (Mm03030144_
g1), Nrf2 (Mm 00477784_m1), catalase (Mm00437992_m1), 
and NQO1 (Mm01253561_m1) (Applied Biosystems, Foster 
City, CA, USA) and designed probes for Atf4 (forward-5′- 
GGGTTCTGTCTTCCACTCCA-3′, reverse-5′-AAGCAGCAG 
AGTCAGGCTTTC-3′), CHOP/Ddit3 (forward-5′-CCACCACA 
CCTGAAAGCAGAA-3′, reverse-5′-AGGTGAAAGGCAGGGA 
CTCA-3′), spliced XBP1 (sXBP1) (forward-5′-CTGAGTCCGA 
ATCAGGTGCAG-3′, reverse-5′-GTCCATGGGAAGATGTT 
CTGG-3′), ferritin heavy chain (forward-5′-AGACCGTGAT 
GACTGGGAGA-3′, reverse-5′-TGAAGTCACATAAGTGGG 
GATCA-3′), and GAPDH (forward-5′-TGCACCACCAACT 
GCTTAGC-3′, reverse-5′-GGCATGGACTGTGGTCATGAG-3′) 
(Fisher Scientific, Spain). Expression levels are given as ratios to 
eukaryotic 18S rRNA (VIC, 4310893E).
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Western Blot
Tissue samples were homogenized in lysis buffer (50 mM of 
Tris–HCl, 150 mM of NaCl, 2 mM of EDTA, 2 mM of EGTA, 
0.2% Triton X-100, 0.3% NP-40, 0.1 mM of PMSF, and 1 µg/ml 
of pepstatin A) and then separated by 10% SDS-PAGE under 
reducing conditions. After electrophoresis, samples were 
transferred to PVDF membranes (IPVH00010, Millipore, 
Bedford, MA, USA), blocked with 5% skimmed milk in 
TBS/0.5% v/v Tween 20 for 1 h, washed with TBS/Tween, and 
incubated with anti-HO-1 (1:2000 dilution, ADI-OSA-150-D 
Enzo Life Technologies), rabbit anti-ferritin light chain (1:500 
dilution, ab69090, Abcam), rabbit anti-ferritin heavy chain 
(1:1000 dilution, Thermo Fisher 701934), and anti-phospho Nrf2 
(1:1000 dilution, bs-2013R, Bioss). Antibodies were diluted in 
5% milk TBS/Tween. Blots were washed with TBS/Tween and 
incubated with anti-rabbit horseradish peroxidase-conjugated 
secondary antibody (1:2000, Amersham, Aylesbury, UK). After 
being washed with TBS/Tween, blots were developed with 
the chemiluminescence method (ECL Luminata Crescendo, 
WBLUR0500, Millipore) and scanned using the ImageQuant 
LAS-4000 (GE Healthcare). Blots were then probed with mouse 
monoclonal anti-α-tubulin antibody (1:5000, T6199, Sigma, 
MO, USA), and levels of expression were corrected for minor 
differences in loading. Quantification was expressed as arbitrary 
densitometric units (AU).
Assessment of Oxidative Stress
The molecular probe 2′,7′-dichlorodihydrofluorescein diacetate 
(H2DCFDA) (C6827; Invitrogen) was used to measure 
intracellular reactive oxygen species (ROS). Cells were incubated 
with H2DCFDA (5 µM) for 30 min, and ROS production was 
estimated using flow cytometry as previously reported (Rubio-
Navarro et al., 2018). To determine cell superoxide anion 
production, cells were assayed with dihydroethidium (DHE) 
(Invitrogen) (Sastre et al., 2013). To quantify mitochondrial 
superoxide production, cells were incubated with MitoSOX Red 
(0.5 µM) for 30 min in the dark. Nuclei were counterstained 
with DAPI. Cells were then analyzed using confocal microscope 
(Leica TCS SP5).
Cell Viability Assay
Cell viability was determined using the 3-[4,5-dimethylthiazol-
2-yl]-2,5 diphenyltetrazolium bromide (MTT, Sigma) colorimetric 
assay. After treatment, cells were incubated with 1 mg/ml of MTT 
in PBS for 1 h at 37°C. The resulting formazan crystals were dried 
and dissolved in dimethylsulfoxide. Absorbance (indicative of 
cell viability) was measured at 570 nm in a microplate reader 
(BMG Labtech Offenburg, Germany).
GSH Measurement
GSH quantification was performed as previously described 
(Kamencic et al., 2000). In brief, cells were incubated with 
monochlorobimane (100 µM) in free serum media for 45 min. Then, 
cells were washed twice with RPMI and treated for 6 h. Fluorescence 
intensity was measured in a Fluostar optima microplate reader 
(BMG Labtech Offenburg, Germany) at excitation and emission 
wavelengths of 410 and 485 nm, respectively.
Statistical Analysis
Data were expressed as mean ± SEM. Differences between groups 
were analyzed with the Kruskal–Wallis test and the Mann–Whitney 
U-test. p values <0.05 were considered significant. Statistical 
analysis was performed using SPSS 11.0 statistical software.
RESULTS
Nrf2 Is Activated in Human Kidney After 
Massive Intravascular Hemolysis
To determine whether Nrf2 is activated in kidneys as consequence 
of intravascular hemolysis, we performed histological studies in a 
patient with AKI-associated with intravascular hemolysis. Perls’ 
Prussian blue staining revealed iron accumulation in tubular 
cells compared with renal tissue from healthy donor (Figure 
1A). Immunofluorescence studies confirmed the presence of 
Hb within tubular cells, as well as Nrf2 phosphorylation and 
translocation to nuclei and induction of HO-1 expression as 
compared with those of healthy control (Figure 1B). In this 
patient, we also observed increased tubular cell death, determined 
by TUNEL staining (Figure 1B), and exacerbated oxidative 
stress, as determined by 4-hydroxynonenal (4-HNE) staining 
(Figure 1C) and presence of the endoplasmic reticulum stress 
markers BiP (binding immunoglobulin protein) (Figure 1D) 
and calnexin (Figure 1E). These results suggest that kidney Hb/
iron accumulation as a consequence of intravascular hemolysis 
promotes oxidative stress and tubular cell injury and further 
activation of Nrf2 in human disease.
Hb/Heme Induces Nrf2 Activation in 
Both AREc32 Cells and Cultured Tubular 
Epithelial Cells
To further explore how intravascular hemolysis modulates Nrf2 
activity, we studied whether Hb and heme directly induce Nrf2 
transcriptional activity in AREc32 cells. In these experiments, we 
observed that Hb or heme increased Nrf2-dependent luciferase 
reporter activity in a dose-dependent manner (Figure 2A and 
B). Moreover, we found that both Hb and heme induced Nrf2 
mRNA expression and Nrf2 nuclear translocation and reduced 
the intracellular levels of the Nrf2 repressor Keap1 in a time-
dependent manner in MCT (Figure 2C–H). Stimulation of MCT 
cells with Hb and heme increased mRNA and protein expression 
of two Nrf2-regulated proteins, HO-1 and ferritin subunits, heavy 
(FtH) (Supplemental Figure 3A–C) and light ferritin chain (FtL) 
(Figure 2I–L).These results suggest that intravascular hemolysis 
activates Nrf2 in the kidney via Hb and heme accumulation.
Nrf2 Is a Protective Factor Against Kidney 
Injury Induced by Intravascular Hemolysis
To determine whether Nrf2 plays a protective role against 
hemolysis-induced kidney injury, we set up a mouse model of 
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FIGURE 1 | Nuclear factor erythroid-2-related factor 2 (Nrf2) activation in a patient with massive intravascular hemolysis-associated acute kidney injury (AKI). 
(A) Representative image of Perls’ Prussian blue staining showing iron accumulation in the renal biopsy of a patient with massive intravascular hemolysis as 
compared with healthy control (200× upper panel, 400× lower panel). (B) Representative confocal microscopy images showing Hb accumulation (green, first 
row), terminal deoxynucleotidyl transferase (TdT) dUTP nick-end labeling (TUNEL)-positive cells (green, second row), phospho-Nrf2 (green, third row), and 
HO-1 (green, fourth row). Nuclei were stained with 4′-6-diamidino-2-phenylindole (DAPI) (blue); scale bar, 100 μm. B.1. Representative confocal microscopy 
images showing the presence of heme cast (red) and nuclear phospho-Nrf2 (green); scale bar, 50 μm. B.2. Representative serial immunofluorescence images 
showing nuclear Nrf2 translocation (phospho-Nrf2, green) in HO-1-rich areas. White circles indicate similar regions in serial immunostained sections. Scale bar, 
100 μm. (C) Representative image of 4-hydroxynonenal (4-HNE) staining (200× upper panel, 400× lower panel). Representative confocal microscopy images 
showing the presence of nuclear Nrf2 translocation (phospho-Nrf2, green) and the endoplasmic reticulum stress markers BiP (red, D) and calnexin (red, E). 
Scale bar, 50 μm.
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FIGURE 2 | Continued
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intravascular hemolysis induced by the intraperitoneal injection 
of phenylhydrazine in wild-type (Nrf2+/+) and Nrf2 knockout 
mice (Nrf2−/−) (Figure 3A). This is a well-established mouse 
model of AKI-associated with massive intravascular hemolysis 
promoted by phenylhydrazine-mediated lipid peroxidation of 
erythrocytes membranes, leading to the extracellular release of 
Hb and heme (Merle et al., 2018). In line with the human findings, 
we observed nuclear staining for phospho-Nrf2 (Ser40) (pNrf2) 
in kidneys from Nrf2+/+ mice with intravascular hemolysis 
(Supplemental Figure 1). Interestingly, our results show a decline 
of renal function (increase of serum creatinine and BUN levels) 
after induction of intravascular hemolysis in WT mice; and this 
was more severe in Nrf2−/− mice (Figure 3B and C). Similarly, 
we observed more severe histological changes (presence of 
intratubular debris, pyknotic nuclei from apoptotic cells, tubular 
epithelial cells into the lumen, and loss of nuclei in the tubular 
epithelium) and enhanced mRNA expression of the tubular injury 
biomarkers NGAL and KIM-1 in Nrf2−/− mice with intravascular 
hemolysis than in wild-type mice (Figure  3D–F). These data 
suggest that Nrf2 could be a protective factor against kidney injury 
promoted by intravascular hemolysis.
We next examined whether Nrf2 deficiency determines 
degree of systemic intravascular hemolysis. As expected, 
phenylhydrazine-injected mice showed a reduction in hematocrit 
and erythrocyte number, as well as an increased concentration 
of serum free Hb and heme, but no significant differences were 
observed between Nrf2+/+ and Nrf2−/− mice (Figure 3G–K). 
Hemolysis also promoted a similar renal accumulation of Hb 
and heme between mice strains, mainly in tubular cells (Figure 
3L–N). Altogether, these data reveal that Nrf2 did not prevent 
erythrocyte lysis or Hb accumulation after the intravascular 
hemolysis episode.
Nrf2 Protects From Kidney Oxidative 
Stress and Cell Death Promoted by 
Intravascular Hemolysis
To fully address the mechanism involved in Nrf2-mediated renal 
protection against intravascular hemolysis, we characterized 
oxidative stress and cell death, pathogenic processes characteristic 
of this scenario (Gutteridge, 1986; Gonzalez-Michaca et al., 
2004). Intraperitoneal phenylhydrazine injection increased renal 
levels of 4-HNE, a marker of lipid peroxidation (Figure 4A), and 
decreased kidney GSH contents (Figure 4B). These effects were 
more severe in Nrf2−/− than in wild-type mice. Recently, ER 
stress has been shown as a new mechanism underlying the renal 
toxicity induced by Hb and heme accumulation (Deuel et al., 
2016; Feng et al., 2018). We observed an increase in expression 
of UPR-related proteins such as CHOP, ATF4, and sXBP1 in 
kidney from WT mice injected with Phe. However, Nrf2−/− mice 
injected with phenylhydrazine showed a higher induction of 
these UPR-related genes (Figure 4C). Renal tubule cell death is an 
important consequence of Hb accumulation, leading to AKI and 
renal failure in patients with intravascular hemolysis (Guerrero-
Hue et al., 2017). Therefore, we explored the potential beneficial 
effect of the Nrf2 transcription factor on cell death prevention. 
Intraperitoneal injection of phenylhydrazine induced tubular cell 
death, as determined by TUNEL-positive staining, in wild-type 
mice, an effect that was significantly increased in Nrf2−/− mice 
(Figure 4D).
Next, to unravel the mechanism involved in Nrf2 protection, 
we analyzed the expression of some Nrf2-regulated genes, such 
as HO-1 and ferritin, which are implicated in the intracellular 
degradation of toxic heme (Stocker, 1990). Intravascular hemolysis 
upregulated HO-1 and both ferritin subunits, light ferritin 
(FtL) (Figure 5A–F) and heavy ferritin (FtH) (Supplemental 
Figure 3D). However, this compensatory response, consisting of 
heme-related and anti-oxidant proteins, was attenuated in Nrf2−/− 
as compared with wild-type mice, despite the more severe injury in 
Nrf2−/− mice. Similar effects were observed for other antioxidant 
Nrf2-dependent genes, such as catalase and NQO1 (Figure 5G 
and H). These results could explain why intravascular hemolysis 
induced more severe kidney injury in mice lacking Nrf2.
Nrf2 Activation Protects Against Hb/
Heme-Mediated Oxidative Stress and Cell 
Death In Vitro
We further investigated whether the Nrf2 inducers sulforaphane 
or tert-butylhydroquinone (tBHQ) protected MCT cells from 
Hb/heme-mediated damage. Thus, we performed in vitro 
experiments pre-treating MCT cells with sulforaphane or tBHQ 
for 16 h before adding Hb/heme. As expected, Nrf2 activators 
increased mRNA and protein HO-1 expression in time- and 
dose-dependent manner (Figure 6A–C). Importantly, we observed 
that sulforaphane and tBHQ reduced Hb- and heme-mediated 
ROS production, i.e., hydrogen peroxide (Figure 6D and E), 
mitochondrial superoxide (Figure 6F), and total superoxide 
(Figure 6G). Similarly, we found that pre-treatment with Nrf2 
inducers abolished the Hb- and heme-mediated intracellular 
GSH reduction (Figure 6H). We next tested whether Nrf2 
activation could protect tubular cells from cell death in vitro. 
FIGURE 2 | Hemoglobin and heme promote Nrf2 activation in cultured renal cells. Nrf2 transcriptional activity was measured by a luciferase reporter assay in 
AREc32 cells treated with increasing concentrations of Hb (0–500 µg/ml, 0–30 µM heme equivalents) (A) or heme (0–10 µM) (B) for 24 h. Representative confocal 
microscopy images showing Nrf2 nuclear translocation (green) in murine tubular (MCT) cells after exposure to Hb (500 µg/ml, 30 µM heme equivalents) (C) or heme 
(1 µM) (D) at different times (0–6 h). Nuclei were stained with DAPI (blue). Nrf2 mRNA expression measured by real-time-quatitative polymerase chain reaction 
(RT-qPCR) in MCT cells treated with Hb (E) or heme (F) for 6 h. (G) Nuclear Nrf2 levels in MCT cells treated with Hb (500 µg/ml, 30 µM heme equivalents) and 
heme (1 µM) at different times (0–6 h). Representative western blot image from nuclear protein fraction. TFIIB (transcription factor II B) was used as loading control. 
(H) Keap1 protein content in MCT cells treated with Hb (500 µg/ml, 30 µM heme equivalents) and heme (1 µM) at different times (0–6 h). HO-1 (I) and FtL (J) mRNA 
expression measured by RT-qPCR in MCT cells treated with heme for 6 h. (K–L) Representative western blot image showing HO-1 and FtL expression in MCT cells 
treated with Hb (0–500 µg/ml, 0–30 µM heme equivalents) and heme (0–10 µM) for up to 48 h (upper panel). Quantification of HO-1 and FtL by western blot (lower 
panel). Results are expressed as mean ± SE. *p < 0.05 vs non-treated cells.
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FIGURE 3 | Nrf2 plays a protective role against kidney injury associated with intravascular hemolysis. C57BL/6 (Nrf2+/+) or Nrf2−/− mice (12 weeks old) were i.p. 
injected with saline (vehicle) or phenylhydrazine (Phe, 2 mg/10 g of body weight) to induce intravascular hemolysis (n = 8/group). (A) Schematic representation of 
intravascular hemolysis mouse model. Serum measurement of creatinine (B) and blood urea nitrogen (BUN) (C). (D) Representative images showing hematoxylin 
and eosin staining in kidneys from mice with intravascular hemolysis. Arrows indicate signs of acute tubular injury: presence of intratubular debris, pyknotic nuclei 
from apoptotic cells, tubular epithelial cells into the lumen, and loss of nuclei in the tubular epithelium. Expression of tubular injury biomarkers NGAL (E) and 
KIM-1 (F), as determined by real-time RT-qPCR, in kidneys from mice with intravascular hemolysis. (G) Representatives images showing kidneys (upper row) and 
serum (lower row) after intravascular hemolysis in both Nrf2+/+ and Nrf2−/− mice. Hematocrit (H), total red blood cell (RBC) counts (I), serum levels of Hb (J) and 
heme (K), and heme concentrations in renal tissue (L). (M) Semi-quantification of hemoglobin (Hb)-positive staining per renal cross section. (N) Representative 
images showing Hb (green) accumulation obtained by confocal microscopy. The podocyte marker nephrin (red) was used to delimitate the glomerular area. Nuclei 
were stained with DAPI (blue); scale bar, 100 μm. Results are expressed as mean ± SE. *p < 0.05 vs Nrf2+/+ control mice, ≠p < 0.05 vs Nrf2+/+ Phe-injected mice.
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Treatment with sulforaphane and tBHQ improved cell viability 
after exposure to heme (Figure 6I and J). Altogether, our 
results show that pharmacological activation of Nrf2 in vitro 
avoided Hb- and heme-mediated oxidative stress and cell death, 
indicating that Nrf2 could be a therapeutic target against kidney 
injury induced by intravascular hemolysis.
In Vivo Nrf2 Activation Protects Against 
Intravascular Hemolysis-Associated AKI
Once we demonstrated the beneficial effects of Nrf2 activation 
in vitro, we tested whether this therapeutic approach may 
prove effective in vivo. Thus, in a first set of experiments, we 
administrated sulforaphane once a day for 3 days to analyze 
FIGURE 4 | Nrf2 protects against oxidative stress and cell death associated with intravascular hemolysis. C57BL/6 (Nrf2+/+) or Nrf2−/− mice (12 weeks old) were 
i.p. injected with saline (vehicle) or phenylhydrazine (Phe, 2 mg/10 g of body weight) to induce intravascular hemolysis (n = 8/group). (A) Representative image of 
4-hydroxynonenal (4-HNE) staining. Semi-quantification of 4-HNE-positive staining per renal cross section. (B) GSH content in renal tissue. (C) ATF4, CHOP, and 
sXBP1 mRNA levels determined in kidney by real-time RT-qPCR. (D) Representative confocal microscopy images showing nuclear staining of TUNEL (green) (left 
panel). Nuclei were stained with DAPI (blue); scale bar, 100 μm. Semi-quantitative analysis of TUNEL-positive cells (right panel). Results are expressed as mean ± 
SE. *p < 0.05 vs Nrf2+/+ control mice, ≠p < 0.05 vs Nrf2+/+ Phe-injected mice.
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whether this treatment produced Nrf2 activation in kidney. 
As reported in Figure 7A, sulforaphane treatment induced 
Nrf2 phosphorylation and increased HO-1 and FtL levels 
in the kidney. We also ruled out any sulforaphane-derived 
adverse effect in the kidney (Supplemental Figure 2). We 
next conducted new experiments to determine whether 
sulforaphane administration protects from phenylhydrazine-
mediated renal injury in mice (Figure 7B). Consistent with 
our previous findings, sulforaphane treatment improved 
renal function in mice with hemolysis, as assessed by 
serum creatinine and BUN (Figure 7C and D). Moreover, 
sulforaphane reduced histological injury (Figure 7E) and 
decreased the gene expression of the tubular injury markers 
KIM-1 and NGAL (Figure 7F and G). In line with our previous 
results, we did not observe any differences in the severity of 
hemolysis (hematocrit, erythrocyte number, and serum free 
Hb/heme concentration) between sulforaphane-treated and 
non-treated mice (Figure 7H–L). Moreover, kidney Hb/
heme accumulation did not change according to sulforaphane 
treatment (Figure 7M and N).
FIGURE 5 | Nrf2-related proteins in kidney from mice with intravascular hemolysis. C57BL/6 (Nrf2+/+) or Nrf2−/− mice (12 weeks old) were i.p. injected with saline 
(vehicle) or phenylhydrazine (Phe, 2 mg/10 g of body weight) to induce intravascular hemolysis (n = 8/group). (A) Representative immunofluorescence images 
obtained by confocal microscopy showing expression of HO-1 (green, upper panel) and FtL (green, lower panel). Nuclei were stained with DAPI (blue); scale bar, 
100 μm. HO-1 (B) and FtL (C) mRNA expression measured by RT-qPCR. Semi-quantification of HO-1 (D) and FtL (E) protein expression determined by western 
blot. (F) Representative western blot image of HO-1 amd FtL expression in kidneys from mice of the experimental model. Catalase (G) and NQO1 (H) mRNA 
expression measured by RT-qPCR. Results are expressed as mean ± SEM. *p < 0.05 vs Nrf2+/+ control mice, ≠p < 0.05 vs Nrf2+/+ Phe-injected mice.
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FIGURE 6 | In vitro Nrf2 induction ameliorates oxidative stress and cell death. HO-1 mRNA and protein expression in MCT cells treated with the Nrf2 inducers 
tert-butylhydroquinone (tBHQ) (A) or sulforaphane (SFN) (B) at different concentrations (µM) for up to 18 h. (C) Representative confocal microscopy images 
showing HO-1 (green) staining in MCT cells pre-treated with Nrf2 inducers SFN and tBHQ with or without Hb. Nuclei were stained with DAPI (blue); scale bar, 
20 μm. Quantification of ROS production (hydrogen peroxide) by flow cytometry with the fluorescent dye H2DCFDA in MCT cells stimulated with Hb (D) or heme (E) 
for 6 h. (F) Representative image of MitoSOX showing mitochondrial superoxide production by Hb (left panel) and heme (right panel) in cells pre-treated with SFN 
(2 µM) and tBHQ (1 µM) for 16 h. Nuclei were stained with DAPI (blue); scale bar, 20 μm. (G) Representative image of superoxide anion production determined by 
confocal microscopy using dihydroethidium (DHE) assay. Nuclei were stained with DAPI (blue); scale bar, 20 μm. (H) Intracellular GSH content in MCT cells treated 
with heme (1 μM) for 6 h with or without SFN (2 μM) or tBHQ (1 µM). (I–J) Cell viability determined in MCT cells stimulated with heme (1 μM) for 24 h and pre-treated 
with SFN (2 μM) or tBHQ (1 µM). Results are expressed as mean ± SEM. *p < 0.05 vs non-treated cells. ≠p < 0.05 vs Hb or heme-treated cells.
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FIGURE 7 | SFN treatment ameliorates acute kidney injury and tubular damage induced by intravascular hemolysis. (A) C57BI/6 mice (males, 12 weeks old) were 
i.p. treated with saline or sulforaphane (SFN, 12.5 mg/kg) for 3 days (n = 5/group). Representative western blot image showing phospho-Nrf2 (Ser40), HO-1, 
and FtL protein expression. (B) C57BI/6 mice (males, 12 weeks old) were i.p. treated with saline or sulforaphane (SFN, 12.5 mg/kg) for 48, 24, and 2 h before 
phenylhydrazine (n = 5/group). Mice were sacrificed 24 h after phenylhydrazine administration. Schematic representation of intravascular hemolysis mouse model. 
Serum measurement of creatinine (C) and blood urea nitrogen (BUN) (D). Representative images showing hematoxylin and eosin staining (E). Expression of 
tubular injury biomarkers NGAL (F) and KIM-1(G), as determined by real-time RT-qPCR, in kidneys from mice with intravascular hemolysis. (H) Representatives 
images showing kidney and serum after intravascular hemolysis in mice treated with SFN. Hematocrit (I) and total red blood cell (RBC) counts (J). Serum levels 
of Hb (K) and heme (L). (M) Heme concentrations in renal tissue. (N) Representative images showing hemoglobin (Hb, green) accumulation obtained by confocal 
microscopy (left panel). The podocyte marker nephrin (red) was used to delimitate the glomerular area. Nuclei were stained with DAPI (blue); scale bar, 100 μm. 
Semi-quantification Hb-positive staining per cross section (right panel). Results are expressed as mean ± SEM. *p < 0.05 vs control mice, ≠p < 0.05 vs Phe-injected mice.
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Interestingly, 4-HNE staining revealed lower oxidative stress 
in sulforaphane-treated than non-treated mice (Figure 8A). In 
addition, sulforaphane decreased the renal expression of UPR-
related molecules induced by intravascular hemolysis (Figure 8B). 
Moreover, the decrease in renal GSH levels was milder in 
sulforaphane-treated mice with hemolysis and was not significantly 
different from that in controls as opposed to the significant GSH 
decrease observed in non-treated mice with hemolysis (Figure 8C). 
Finally, we observed that sulforaphane significantly decreased renal 
tubular epithelial cell death, evaluated by TUNEL staining, after 
intravascular hemolysis, as compared with that in non-treated 
mice (Figure 8D and E). Collectively, these results suggest that 
administration of the pharmacologic inducer of Nrf2, sulforaphane, 
relieves the kidney adverse effects observed in experimental 
hemolysis. We conclude that Nrf2 might be a potential therapeutic 
target for kidney injury induced by intravascular hemolysis. 
FIGURE 8 | Nrf2 activation pathway in kidney from SFN-treated mice. (A) Representative image of 4-HNE staining in the experimental model (left). Semi-quantification 
4-HNE-positive staining per cross section (right). (B) ATF4, CHOP, and sXBP1 mRNA levels determined in kidney by real-time RT-qPCR. (C) GSH content in renal 
tissue. (D) Representative confocal microscopy images showing nuclear staining of TUNEL (green) (left) and semi-quantitative analysis of TUNEL-positive cells (right). 
Nuclei were stained with DAPI (blue); scale bar, 100 μm. Results are expressed as mean ± SEM. *p < 0.05 vs control mice, ≠p < 0.05 vs Phe-injected mice.
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DISCUSSION
In the present study, we demonstrate that Hb/heme accumulation 
in the kidney after massive intravascular hemolysis induces 
Nrf2 activation. We also found that massive intravascular 
hemolysis promotes AKI, resulting in increased serum creatinine 
concentration, tubular injury, oxidative and ER stress, and 
subsequent kidney cell death. These harmful effects were more 
severe in Nrf2 knockout mice, which showed a decreased 
expression of the Nrf2-dependent antioxidant proteins HO-1, 
FtL, and FtH and reduced levels of GSH, suggesting a critical 
protective role against Hb-mediated ROS production and cell 
toxicity in the kidney. Moreover, therapeutic Nrf2 activation 
reduced Hb/heme-mediated cellular stress and cytotoxicity 
in experimental hemolysis and cultured renal cells. Therefore, 
enhancing Nrf2 activity may be a potential therapeutic strategy 
to decrease renal injury associated with hemolytic diseases.
Recurrent or massive erythrocyte lysis increases plasma free 
Hb concentration and leads to renal Hb overload and toxicity, 
contributing to acute and chronic kidney injury (Tracz et al., 
2007; Moreno et al., 2012; Naik et al., 2014). In our study, we 
administrated phenylhydrazine to induce severe hemolysis, 
thus promoting accumulation of Hb and its heme derivatives 
as well as a rapid decrease of renal function. It is well known 
that Hb triggers ROS production (Jia et al., 2007), similar to 
our observations in renal proximal tubular epithelial cells after 
exposure with Hb or heme. Recently, ER stress has been shown 
as a novel mechanism underlying the renal toxicity of Hb 
and heme (Deuel et al., 2016; Feng et al., 2018). Interestingly, 
Nrf2−/− mice showed an exacerbated renal expression of UPR-
related genes, suggesting a protective role of this transcription 
factor against ER stress in kidney. Mitochondria are susceptible 
to Hb-mediated toxicity, resulting in decreased oxygen 
consumption and exacerbating mitochondrial ROS production 
(Nath et al., 1998). In this line, our results show an increased 
mitochondrial ROS production in renal cells exposed to Hb 
and heme. We also found that Hb/heme-mediated oxidative 
stress was related not only to production of superoxide 
anion and hydrogen peroxide but also to a reduction in GSH 
levels, the main cellular antioxidant. There is accumulating 
evidence supporting a direct link between mitochondria, 
oxidative stress, and cell death (Ott  et al., 2007). Previous 
studies from our group showed that Hb induced apoptosis in 
renal podocytes by mitochondrial-related intrinsic pathway 
(Rubio-Navarro et al., 2018). Moreover, it has been shown that 
oxidative stress may contribute to ER stress and subsequent 
cell death (Liu et al., 2019). Specifically, rhabdomyolysis-
induced ER stress promoted apoptosis, playing a crucial 
role in progression of AKI (Feng et al., 2018). According 
to these observations, the oxidative and ER stress as well as 
mitochondrial oxidation induced by Hb/heme may explain the 
increased cell death rate reported in our study, both in vitro 
and in mice with intravascular hemolysis (Nath et al., 1995; 
Gonzalez-Michaca et al., 2004). Moreover, this could explain 
the exacerbated cell death observed in kidney from Nrf2−/−, 
suggesting a protective role against renal toxicity subsequent 
to intravascular hemolysis.
There is no specific treatment to avoid the toxic effects caused 
by free Hb in the kidney. Therefore, understanding molecular 
mechanisms involved in this pathological setting is crucial to 
design new therapeutic strategies. In this line, Nrf2 has emerged 
as a master regulator of cellular resistance to oxidation (Guerrero-
Hue et al., 2017). In basal conditions, Nrf2 is bound to Keap1, 
a cytosolic repressor that targets Nrf2 to the proteasome for 
degradation (Jaiswal, 2004). However, oxidative stress modifies 
cysteine residues in Keap1 and allows the nuclear translocation 
of Nrf2, such as what we observed in tubular cells stimulated 
with Hb and in mice with hemolysis. Once in the nucleus, 
Nrf2 transcriptionally induces the expression of cytoprotective 
enzymes and proteins involved in heme-degradation, including 
HO-1 and both ferritin subunits, FtH with ferroxidase activity 
and FtL that induces iron nucleation. Thus, we surmised that Nrf2 
might improve intravascular hemolysis-induced kidney injury. To 
test this hypothesis, we induced intravascular hemolysis in both 
Nrf2+/+ and Nrf2−/− mice. Here, we show that mice lacking Nrf2 
gene had more severe kidney injury, characterized by loss of renal 
function and increased cell stress and death. In agreement with 
our data, several studies have demonstrated the protective role 
of Nrf2 in a number of renal diseases associated with oxidative 
stress, such as cisplatin-induced nephropathy (Li et al., 2016), 
ischemia–reperfusion (Bayrak et al., 2008; Yoon et al., 2008; 
Trujillo et al., 2013), and rhabdomyolysis (Zhao et  al.,  2016). 
Oxidative stress drives ER stress and UPR activation in order to 
attenuate cellular stress through Nrf2 activation (Cullinan and 
Diehl, 2004; Liu et al., 2019). Interestingly, our data showed an 
increased expression of UPR-related proteins in kidneys from 
phenylhydrazine-injected Nrf2−/− mice as compared with wild-
type mice, suggesting that the Nrf2 pathway may regulate kidney 
ER stress induced by intravascular hemolysis (Mukaigasa et al., 
2018). In our study, the Nrf2-regulated molecules HO-1, FtL, 
and FtH were found upregulated in kidneys from wild-type mice 
after hemolysis or in cultured tubular epithelial cells stimulated 
with Hb/heme. Supporting the translational relevance of our 
findings, we observed increased Nrf2 and HO-1 expression, lipid 
peroxidation, and tubular cell death in a patient suffering from 
massive Hb renal accumulation after hemolysis-associated AKI. 
Similarly, patients with warm antibody hemolytic anemia, SCD, 
or thrombotic microangiopathy also showed increased expression 
and activity of HO-1 in renal tubules (Nath et al., 2001; Maroti 
et al., 2004; Fervenza et al., 2008). However, it is important to note 
that in our study, kidneys from Nrf2−/− mice with hemolysis 
showed an attenuated adaptive response characterized by lower 
expression of NQO-1, catalase, HO-1, FtH, and FtL than did 
wild-type mice with hemolysis. These Nrf2-regulated proteins 
play a key protective role against heme-mediated oxidative stress. 
HO-1 is the principal enzyme involved in heme degradation 
and, therefore, plays a cytoprotective function during heme-
mediated tissue injury (Vogt et al., 1995). Interestingly, a known 
human case of HO-1 deficiency showed persistent hemolytic 
anemia with kidney iron deposits as well as loss of renal 
function (Yachie et al., 1999). Altogether, these data suggest 
the key role of the Nrf2/HO-1 axis in renal diseases associated 
with Hb accumulation. Recent studies have demonstrated 
the relevance of Nrf2 pathway in the regulation of hemolysis 
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(Keleku-Lukwete et al., 2015; Krishnamoorthy et al., 2017). Thus, 
targeted disruption of Nrf2 induced hemolytic anemia in old 
mice by increasing erythrocyte susceptibility to oxidative stress 
(Lee et al., 2004). However, young Nrf2−/− mice did no present 
anemia (Chan et al., 1996). There are also conflicting reports on 
whether Nrf2 activation reduces hemolysis or not. Thus, the Nrf2 
agonist dimethyl fumarate improved hematological parameters 
and reduced plasma-free Hb in SCD mice (Krishnamoorthy 
et al., 2017), whereas other authors showed that Nrf2 activation 
through ablation of its negative regulator Keap1 did not modify 
hemolysis and stress erythropoiesis in SCD mice, although it 
increased plasma heme clearance (Keleku-Lukwete et al., 2015). 
Our findings show no differences in serum free Hb and heme 
levels between Nrf2−/− and Nrf2+/+ mice or after Nrf2 activation 
with sulforaphane. Moreover, we do not observed differences 
in renal heme concentration according to Nrf2 genotypes or 
sulforaphane treatment. Altogether, these results seem to indicate 
that beneficial effects of Nrf2 on renal function are not related 
with a reduction in hemolysis or an increased heme catabolism 
in massive hemolysis induced by phenylhydrazine.
There is evidence that genetic or pharmacological Nrf2 
activation may ameliorate systemic and vascular inflammation as 
well as lung injury and liver damage in mice with intravascular 
hemolysis (Keleku-Lukwete et al., 2015; Ghosh et al., 2016; 
Promsote et al., 2016; Belcher et al., 2017; Ghosh et al., 2018). 
However, none of these studies focused on renal injury, one of 
the major pathological consequences observed in patients with 
massive and recurrent hemolytic crises (Baddam et al., 2017; 
Mammen et al., 2017; Plewes et al., 2017). To investigate a potential 
beneficial effect of Nrf2 induction in vivo, we treated mice with 
sulforaphane before the onset of hemolysis. Remarkably, Nrf2 
activation with sulforaphane ameliorated renal function and 
decreased oxidative and ER stress, cell viability, and tubular injury 
associated with massive hemolysis. Similar effects were observed 
in cultured tubular cells, where Nrf2 activation with sulforaphane 
or tBHQ reduced cellular and mitochondrial ROS production, 
the loss of GSH, and cell death induced by Hb and heme. These 
protective effects may be explained by an Nrf2-mediated induction 
of HO-1 and ferritin expression, thus decreasing heme-mediated 
toxic effects. In agreement with our data, Nrf2 activation also 
reduced cellular stress such as oxidative stress and ER stress and 
ameliorated renal function in experimental ischemia–reperfusion 
(Bayrak et al., 2008; Yoon et al., 2008; Trujillo et al., 2013) and 
rhabdomyolysis-associated AKI (Zhao et al., 2016; Guerrero-
Hue et al., 2017). Interestingly, although activation of Nrf2 may 
induce UPR (Cullinan and Diehl, 2004; Liu et al., 2019), we did 
not observe significant changes in UPR-related genes in kidney 
from mice treated with sulforaphane compared with non-treated 
mice, suggesting that Nrf2 may activate UPR in the presence of ER 
stress but not in basal conditions. Moreover, different therapeutic 
approaches based on Nrf2 activation have preserved renal function 
in several past and ongoing clinical trials in patients with renal 
disease (Guerrero-Hue et al., 2017). Overall, our findings indicate 
for the first time that Nrf2 could be a potential target to prevent 
renal damage induced by intravascular hemolysis by ameliorating 
oxidative stress, ER stress, tubular cell death, and loss of renal 
function. These protective effects may be mediated almost in part 
by promoting the expression of antioxidant proteins involved in 
heme catabolism, including HO-1 and ferritin. Lack of cell-site-
specific Nrf2 deletion in mice is a limitation of our study. Further 
studies must be performed to test whether specific Nrf2 deletion 
in tubular cells increases renal injury in hemolytic disorders.
In conclusion, our results show that Nrf2 plays a key regulatory 
role in limiting the severity of AKI triggered by intravascular 
hemolysis. Renal Hb accumulation promotes a loss of renal 
function and kidney injury, effects that are aggravated by the 
genetic deletion of Nrf2. Sulforaphane treatment induced Nrf2 
activation as well as an increase of related proteins such as HO-1 
and ferritin, decreasing the severity of kidney injury induced 
by intravascular hemolysis. Thus, Nrf2 could be a potential 
therapeutic target to limit Hb-induced toxicity in patients with 
intravascular hemolysis.
DATA AVAILABILITY STATEMENT
The raw data supporting the conclusions of this manuscript will 
be made available by the authors, without undue reservation, to 
any qualified researcher.
ETHICS STATEMENT
Patients provided informed consent, and the biobank was approved 
by Instituto de Investigaciones Sanitarias-Fundacion Jimenez 
Diaz (IIS-FJD) ethics committee. All reported experiments with 
animals were conducted in accordance with the Directive 2010/63/
EU of the European Parliament and were approved by Instituto de 
Investigaciones Sanitarias-Fundacion Jimenez Diaz Animal Care 
and Use Committee.
AUTHOR CONTRIBUTIONS
AR-N and JM designed the study. AS, CY, and ER were involved 
in human samples collection. PC analyzed renal biopsies. AR-N, 
CV-C, CH, RL, PM, MG-H, SC, MG, JE, IC, CG-C, and BA 
performed research. AR-N, CV-C, MG-H, and JM performed 
data analysis and data interpretation. EG, AR-N, JE, AO, MP, 
and JM wrote the manuscript. All authors critically revised the 
manuscript for important intellectual content.
FUNDING
Supported by FIS/FEDER CP14/00008, CP16/00014, CP16/00017, 
PI15/00448, PI16/00735, PI16/02057, PI17/00130, PI17/01495, 
PI17/01700, ISCIII-RETIC REDinREN RD012/0021, RD016/0009 
FEDER funds, Spanish Ministry of Economy and Competitiveness 
(RYC-2017-22369), Sociedad Española de Nefrología, Fundacion 
Renal Iñigo Álvarez de Toledo (FRIAT), Comunidad de Madrid 
CIFRA2 B2017/BMD-3686 and BMD-3827, Fundacion La Caixa, 
CaixaImpulse program CI17-00048, and Spanish Biomedical 
Research Centre in Diabetes and Associated Metabolic Disorders 
(CIBERDEM).
Nrf2 Reduces Hemoglobin-Induced Renal DamageRubio-Navarro et al.
16 July 2019 | Volume 10 | Article 740Frontiers in Pharmacology | www.frontiersin.org
SUPPLEMENTARY MATERIAL
The Supplementary Material for this article can be found online at: 
https://www.frontiersin.org/articles/10.3389/fphar.2019.00740/
full#supplementary-material
FIGURE S1 | Nrf2 resulted activated in mice with intravascular hemolysis. 
Representative confocal microscopy images showing nuclear translocation of 
phosphorylated-Nrf2 (Ser40) (green) in C57Bl/6 wild type (Nrf2+/+) mice that 
were i.p. injected with saline (Vehicle) or phenylhydrazine (Phe, 2mg/10g of body 
weight) to induce intravascular hemolysis. Nuclei were stained with DAPI (blue), 
scale bar 100 μm.
FIGURE S2 | Expression of NGAL (A) and KIM-1 (B) determined by 
RT-qPCR in kidneys from control mice treated with sulforaphane (SFN, 
12.5 mg/kg) for 3 days. These animals did not display evidence of tubular 
injury as there was no increase in the expression of these markers. (C) 
Quantification of total Nrf2 protein in kidney from control mice and treated 
with SFN (left panel). Representative western blot image showing total Nrf2 
protein levels (right panel). Results are expressed as mean ± SE. *p<0.05 vs 
non-treated cells.
FIGURE S3 | (A) Expression of FtH mRNA expression measured by 
RT-qPCR in MCTs cells treated with heme for 6h. (B) Western blot image 
showing FtH expression in MCT cells treated with Heme (0-10 µM) for 24h. 
(C) FtH protein expression in MCT cells stimulated with Hb (0-500 µg/mL, 
0-30 µM heme equivalents). FtH mRNA expression measured by RT-qPCR 
(D) and semiquantification of FtH protein expression determined by 
western-blot (E) of kidneys from wild type and Nrf2 -/- mice injected with 
phenylhydrazine or vehicle. FtH mRNA expression measured by RT-qPCR 
(F) and semiquantification of FtH protein expression determined by western-
blot (G) of kidneys from wild type pre-treated with SFN and injected with 
phenylhydrazine or vehicle.
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